OBD | Search

Trials

439 participants · First posted Feb 17, 2011

Completed

NCT00595946

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

439 participants · First posted Jan 16, 2008

Completed

NCT00597428

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

437 participants · First posted Jan 18, 2008

Drugs

View all 293 →

CLK1/4 kinase inhibitor (Beth Israel Deaconess Medical Center/Boston Children's Hospital)

OBD9

生物制品

Approved

Isatuximab(Sarclisa)

Conditions: Multiple Myeloma (MM), Refractory Multiple Myeloma +1 more

Organizations

View all 11 →

OAD ORTHOPAEDICS

United States

OLD DOMINION UNIVERSITY

United States

Oba Pharmaceuticals Inc

United States

News

View all 232 →

last year

Oxford BioDynamics Partners with Google Cloud to Scale AI-Powered 3D Genomic Analytics Platform

last year

Oxford Brain Diagnostics Launches Revolutionary MRI-Based Dementia Diagnosis Technology Following FDA and UK Regulatory Approvals

last year

Trials

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

Drugs

CLK1/4 kinase inhibitor (Beth Israel Deaconess Medical Center/Boston Children's Hospital)

OBD9

Isatuximab(Sarclisa)

Organizations

OAD ORTHOPAEDICS

OLD DOMINION UNIVERSITY

Oba Pharmaceuticals Inc

News

Oxford BioDynamics Partners with Google Cloud to Scale AI-Powered 3D Genomic Analytics Platform

Oxford Brain Diagnostics Launches Revolutionary MRI-Based Dementia Diagnosis Technology Following FDA and UK Regulatory Approvals

Yoltech Therapeutics' YOLT-201 Shows Promise in Phase I ATTR Amyloidosis Trial